Treatment patterns and outcomes after neo-adjuvant chemo in MIBC
Research type
Research Study
Full title
Treatment Patterns and Clinical Outcomes following Neo-Adjuvant Treatment in patients with Muscle Invasive Bladder Cancer: A Multicentre Study in the United Kingdom
IRAS ID
357857
Contact name
Emily Jane Clare Renninson
Contact email
Sponsor organisation
Venlindre University NHS Trust
Duration of Study in the UK
1 years, 11 months, 30 days
Research summary
It is hopeful we are on the brink of a leap forward in the definitive management of muscle invasive urothelial carcinoma. It is therefore timely to perform an evaluation of current practice. The purpose of this research is to take stock of the journeys of patients embarking on a curative pathway with neoadjuvant gemcitabine and cisplatin in the United Kingdom between 2022 and 2024. We will look at the response and toxicity of initial neoadjuvant treatments, and the proportion of patients who go on to receive definitive treatment. We will look at the proportion of that definitive treatment that is surgical. We will at which adjuvant treatments are being received, their efficacy and tolerability. We will look at progression free survival and the management of both local and metastatic relapse. The aim of this research is to provide an overview on current practice, to guide future research and study design. No active patient participation will be required during retrospective data collection. Patient confidentiality will be maintained by pseudonymisation of all identifiable patient demographic data and with study-specific codes.
REC name
N/A
REC reference
N/A